- 1Department of Bone and Soft Tissue Oncology, Department of Orthopaedic, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China
- 2The First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, China
A Correction on
Research progress of B7-H3 in malignant tumors
By Zhao S, Zhang H and Shang G (2025). Front. Immunol. 16:1586759. doi: 10.3389/fimmu.2025.1586759
In the published article, there was an error in the Affiliation(s). Instead of “1The First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, China,2Department of Bone and Soft Tissue Oncology, Department of Orthopaedic, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China”, it should be “1Department of Bone and Soft Tissue Oncology, Department of Orthopaedic, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China,2The First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning, China”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: B7-H3(CD276), malignant tumor, targeted therapy, immunity, drug trials
Citation: Zhao S, Zhang H and Shang G (2025) Correction: Research progress of B7-H3 in malignant tumors. Front. Immunol. 16:1641733. doi: 10.3389/fimmu.2025.1641733
Received: 05 June 2025; Accepted: 06 June 2025;
Published: 17 June 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Zhao, Zhang and Shang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Guanning Shang, Y211c2hhbmdnbkAxNjMuY29t
†These authors have contributed equally to this work and share first authorship